PPARα agonists regulate lipid metabolism and nitric oxide production and prevent placental overgrowth in term placentas from diabetic rats

Journal of Molecular Endocrinology

Volumn 47, Issue 1, 2011, Pages 1-12

  Martínez, Nora ^a   Kurtz, Melisa ^a   Capobianco, Evangelina ^a   Higa, Romina ^a   White, Verónica ^a   Jawerbaum, Alicia ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; LEUKOTRIENE B4; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; EXPLANT; FETUS; FETUS DEVELOPMENT; LIPID METABOLISM; LIPID PEROXIDATION; METABOLITE; NEWBORN; NEWBORN PERIOD; NONHUMAN; ORGAN WEIGHT; PLACENTA DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TERM BIRTH; TISSUE CULTURE;

ANIMALS; CHOLESTEROL; CLOFIBRATE; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; FETUS; LEUKOTRIENE B4; LIPID METABOLISM; LIPID PEROXIDATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; ORGAN SIZE; PHOSPHOLIPIDS; PLACENTA; PPAR ALPHA; PREGNANCY; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 79960999898     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-10-0173     Document Type: Article

References (69)

1. Abdelmegeed MA, Moon KH, Hardwick JP, Gonzalez FJ & Song BJ 2009 Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress. Free Radical Biology and Medicine 47 767-778. (doi:10.1016/j.freeradbiomed.2009.06.017)
2. Anwer T, Sharma M, Pillai KK, Haque SE, Alam MM & Zaman MS 2007 Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats. Toxicology 229 165-172. (doi:10.1016/j.tox. 2006.10.016)
3. Arck P, Toth B, Pestka A & Jeschke U 2010 Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials. Biology of Reproduction 83 168-176. (doi:10.1095/biolreprod.110.083550)
4. Balsells M, Garcia-Patterson A, Gich I & Corcoy R 2009 Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 94 4284-4291. (doi:10.1210/jc.2009-1231)
5. Barak Y, Sadovsky Y & Shalom-Barak T 2008 PPAR signaling in placental development and function. PPAR Research 2008 142082. (doi:10.1155/2008/142082)
6. Belfort R, Berria R, Cornell J & Cusi K 2010 Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 95 829-836. (doi:10. 1210/jc.2009-1487)
7. Benameur T, Tual-Chalot S, Andriantsitohaina R & Martinez MC 2010 PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis. PLoS ONE 5 e12392. (doi:10.1371/journal.pone. 0012392)
8. Bensinger SJ & Tontonoz P 2008 Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 470-477. (doi:10.1038/nature07202)
9. Braissant O & Wahli W 1998 Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139 2748-2754. (doi:10. 1210/en.139.6.2748)
10. Capobianco E, Jawerbaum A, Romanini MC, White V, Pustovrh C, Higa R, Martinez N, Mugnaini MT, Sonez C & Gonzalez E 2005 15-Deoxy-delta(12,14)-prostaglandin J2 and peroxisome proliferator- activated receptor gamma (PPARgamma) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPARgamma agonist on nitridergic and lipid placental metabolism. Reproduction, Fertility, and Development 17 423-433. (doi:10.1071/RD04067)
11. Capobianco E, White V, Higa R, Martinez N & Jawerbaum A 2008 Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats. Molecular Human Reproduction 14 491-499. (doi:10.1093/molehr/gan039)
12. Catalano PM & Kirwan JP 2001 Maternal factors that determine neonatal size and body fat. Current Diabetes Reports 1 71-77. (doi:10. 1007/s11892-001-0013-y)
13. Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G & Riccardi C 2008 Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Molecular Pharmacology 73 323-337. (doi:10.1124/mol.107.041475)
14. Desoye G & Shafrir E 1994 Placental metabolism and its regulation in health and diabetes. Molecular Aspects of Medicine 15 505-682. (doi:10.1016/0098-2997(94)90004-3)
15. Desvergne B, Michalik L & Wahli W 2004 Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Molecular Endocrinology 18 1321-1332. (doi:10.1210/me.2004-0088)
16. Dulak J & Jozkowicz A 2003 Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. Antioxidants and Redox Signaling 5 123-132. (doi:10.1089/152308603321223612)
17. Finck BN 2007 The PPAR regulatory system in cardiac physiology and disease. Cardiovascular Research 73 269-277. (doi:10.1016/j.cardiores. 2006.08.023)
18. Fournier T, Handschuh K, Tsatsaris V, Guibourdenche J and Evain-BrionD 2008 Role of nuclear receptors and their ligands in human trophoblast invasion. Journal of Reproductive Immunology 77 161-170. (doi:10.1016/j.jri.2007.05.004)
19. Gatford KL, Simmons RA, De Blasio MJ, Robinson JS & Owens JA 2010 Review: placental programming of postnatal diabetes and impaired insulin action after IUGR. Placenta 31 (Supplement) S60-S65. (doi:10.1016/j.placenta.2009.12.015)
20. Giaginis C, Spanopoulou E & Theocharis S 2008 PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. Expert Opinion on Therapeutic Targets 12 1049-1063. (doi:10.1517/ 14728222.12.8.1049)
21. Giannubilo SR, Menegazzi M, Tedeschi E, Bezzeccheri V, Suzuki H & Tranquilli AL 2008 Doppler analysis and placental nitric oxide synthase expression during fetal growth restriction. Journal of Maternal-Fetal & Neonatal Medicine 21 617-622. (doi:10.1080/ 14767050802214774)
22. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS & Tannenbaum SR 1982 Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Analytical Biochemistry 126 131-138. (doi:10. 1016/0003-2697(82)90118-X)
23. Hein GJ, Bernasconi AM, Montanaro MA, Pellon-Maison M, Finarelli G, Chicco A, Lombardo YB & Brenner RR 2010 Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids. American Journal of Physiology, Endocrinology and Metabolism 298 E429-E439. (doi:10.1152/ajpendo.00513.2009)
24. Herrera E & Ortega-Senovilla H 2010 Disturbances in lipid metabolism in diabetic pregnancy - are these the cause of the problem? Best Practice & Research. Clinical Endocrinology and Metabolism 24 515-525. (doi:10.1016/j.beem.2010.05.006)
25. Hiden U, Glitzner E, Hartmann M & Desoye G 2009 Insulin and the IGF system in the human placenta of normal and diabetic pregnancies. Journal of Anatomy 215 60-68. (doi:10.1111/j.1469- 7580.2008.01035.x)
26. Higa R, White V, Martinez N, Kurtz M, Capobianco E & Jawerbaum A 2010 Safflower and olive oil dietary treatments rescue aberrant embryonic arachidonic acid and nitric oxide metabolism and prevent diabetic embryopathy in rats. Molecular Human Reproduction 16 286-295. (doi:10.1093/molehr/gap109)
27. Hihi AK, Michalik L & Wahli W 2002 PPARs: transcriptional effectors of fatty acids and their derivatives. Cellular and Molecular Life Sciences 59 790-798. (doi:10.1007/s00018-002-8467-x)
28. Holdsworth-Carson SJ, Permezel M, Riley C, Rice GE & Lappas M 2009 Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes. Placenta 30 176-186. (doi:10.1016/j. placenta.2008.11.013)
29. Holdsworth-Carson SJ, Lim R, Mitton A, Whitehead C, Rice GE, Permezel M & Lappas M 2010 Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta 31 222-229. (doi:10.1016/j.placenta.2009. 12.009)
30. Ibarra-Lara L, Cervantes-Perez LG, Perez-Severiano F, Del Valle L, Rubio-Ruiz E, Soria-Castro E, Pastelin-Hernandez GS, Sanchez- Aguilar M, Martinez-Lazcano JC & Sanchez-Mendoza A 2010 PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner. European Journal of Pharmacology 627 185-193. (doi:10.1016/j.ejphar. 2009.10.039)
31. Inoue I, Noji S, Shen MZ, Takahashi K & Katayama S 1997 The peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochemical and Biophysical Research Communications 237 606-610. (doi:10.1006/bbrc.1997.7196)
32. Jansson T, Cetin I, Powell TL, Desoye G, Radaelli T, Ericsson A & Sibley CP 2006 Placental transport and metabolism in fetal overgrowth - a workshop report. Placenta 27 (Supplement A) S109-S113. (doi:10.1016/j.placenta.2006.01.017)
33. Jawerbaum A & Gonzalez E 2005 The role of alterations in arachidonic acid metabolism and nitric oxide homeostasis in rat models of diabetes during early pregnancy. Current Pharmaceutical Design 11 1327-1342. (doi:10.2174/1381612053507503)
34. Jawerbaum A & Gonzalez E 2006 Diabetic pregnancies: the challenge of developing in a pro-inflammatory environment. Current Medicinal Chemistry 13 2127-2138. (doi:10.2174/09298670 6777935302)
35. Jawerbaum A & White V 2010 Animal models in diabetes and pregnancy. Endocrine Reviews 31 680-701. (doi:10.1210/er.2009- 0038)
36. Kurtz M, Capobianco E, Martinez N, Fernandez J, Higa R, White V & Jawerbaum A 2010 Carbaprostacyclin, a PPARdelta agonist, ameliorates excess lipid accumulation in diabetic rat placentas. Life Sciences 86 781-790. (doi:10.1016/j.lfs.2010.03.008)
37. Lappas M & Rice GE 2009 Transcriptional regulation of the processes of human labour and delivery. Placenta 30 (Supplement A) S90-S95. (doi:10.1016/j.placenta.2008.10.005)
38. Leach L, Taylor A & Sciota F 2009 Vascular dysfunction in the diabetic placenta: causes and consequences. Journal of Anatomy 215 69-76.(doi:10.1111/j.1469-7580.2009.01098.x)
39. Lefebvre P, Chinetti G, Fruchart JC & Staels B 2006 Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. Journal of Clinical Investigation 116 571-580. (doi:10.1172/ JCI27989)
40. Lin Q, Ruuska SE, Shaw NS, Dong D & Noy N 1999 Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 38 185-190. (doi:10.1021/bi9816094)
41. Lin H, Hou CC, Cheng CF, Chiu TH, Hsu YH, Sue YM, Chen TH, Hou HH, Chao YC, Cheng TH et al. 2007 Peroxisomal proliferatoractivated receptor-alpha protects renal tubular cells from doxorubicin- induced apoptosis. Molecular Pharmacology 72 1238-1245. (doi:10.1124/mol.107.037523)
42. Martinez N, Capobianco E, White V, Pustovrh MC, Higa R & Jawerbaum A 2008 Peroxisome proliferator-activated receptor alpha activation regulates lipid metabolism in the feto-placental unit from diabetic rats. Reproduction 136 95-103. (doi:10.1530/REP- 08-0028)
43. Martinez N, White V, Kurtz M, Higa R, Capobianco E & Jawerbaum A 2011 Activation of the nuclear receptor PPARalpha regulates lipid metabolism in foetal liver from diabetic rats: implications in diabetes-induced foetal overgrowth. Diabetes Metabolism Research and Reviews 27 35-46. (doi:10.1002/dmrr.1151)
44. Melamed N & Hod M 2009 Perinatal mortality in pregestational diabetes. International Journal of Gynaecology and Obstetrics 104 (Supplement 1) S20-S24. (doi:10.1016/j.ijgo.2008.11.024)
45. MichaelWeindling A 2009 Offspring of diabetic pregnancy: short-term outcomes. Seminars in Fetal and Neonatal Medicine 14 111-118. (doi:10.1016/j.siny.2008.11.007)
46. Myatt L & Cui X 2004 Oxidative stress in the placenta. Histochemistry and Cell Biology 122 369-382. (doi:10.1007/s00418-004-0677-x)
47. Narala VR, Adapala RK, Suresh MV, Brock TG, Peters-Golden M & Reddy RC 2010 Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. Journal of Biological Chemistry 285 22067-22074. (doi:10. 1074/jbc.M109.085118)
48. Nowicki MJ, Shi D, Cai Z, Bishop PR & May WL 2003 Developmental expression of endothelial nitric oxide synthase (eNOS) in the rat liver. Pediatric Research 54 732-738. (doi:10.1203/01.PDR. 0000086904.52847.2A)
49. Ohkawa H, Ohishi N & Yagi K 1979 Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 95 351-358. (doi:10.1016/0003-2697(79)90738-3)
50. Panadero MI, Gonzalez MC, Herrera E & Bocos C 2009 Factors modulating fibrates response: therapeutic implications and alternative strategies. Endocrine, Metabolic and Immune Disorders Drug Targets 9 219-236. (doi:10.2174/187153009789044356)
51. Parast MM, Yu H, Ciric A, Salata MW, Davis V & Milstone DS 2009 PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation. PLoS ONE 4 e8055. (doi:10. 1371/journal.pone.0008055)
52. Paukkeri EL, Leppanen T, Sareila O, Vuolteenaho K, Kankaanranta H & Moilanen E 2007 PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. British Journal of Pharmacology 152 1081-1091. (doi:10. 1038/sj.bjp.0707477)
53. Plagemann A, Harder T & Dudenhausen JW 2008 The diabetic pregnancy, macrosomia, and perinatal nutritional programming. NestléNutrition Workshop Series. Paediatric Programme 61 91-102. (doi:10.1159/000113179)
54. Portha B, Picon L & Rosselin G 1979 Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 17 371-377. (doi:10.1007/BF01236272)
55. Pustovrh MC, Capobianco E, Martinez N, Higa R, White V & Jawerbaum A 2009 MMP/TIMP balance is modulated in vitro by 15dPGJ(2) in fetuses and placentas from diabetic rats. European Journal of Clinical Investigation 39 1082-1090. (doi:10.1111/j.1365- 2362.2009.02200.x)
56. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, MullerM and Kersten S 2007 Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Research 2007 26839. (doi:10.1155/2007/26839)
57. Reece EA, Leguizamon G & Wiznitzer A 2009 Gestational diabetes: the need for a common ground. Lancet 373 1789-1797. (doi:10.1016/ S0140-6736(09)60515-8)
58. Ringseis R, Gutgesell A, Dathe C, Brandsch C & Eder K 2007 Feeding oxidized fat during pregnancy up-regulates expression of PPARalpha- responsive genes in the liver of rat fetuses. Lipids in Health and Disease 6 6. (doi:10.1186/1476-511X-6-6)
59. San Martin R & Sobrevia L 2006 Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 27 1-10. (doi:10.1016/j. placenta.2005.01.011)
60. Schaiff WT, Carlson MG, Smith SD, Levy R, Nelson DM & Sadovsky Y 2000 Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. Journal of Clinical Endocrinology and Metabolism 85 3874-3881. (doi:10.1210/jc.85.10.3874)
61. van Straten E, van Meer H, Huijkman N, van Dijk TH, Baller JF, Verkade HJ, Kuipers F & Plosch T 2009 Fetal liver X receptor activation acutely induces lipogenesis, but does not affect plasma lipid response to a high-fat diet in adult mice. American Journal of Physiology, Endocrinology and Metabolism 297 E1171-E1178. (doi:10. 1152/ajpendo.00021.2009)
62. Straus DS & Glass CK 2007 Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology 28 551-558. (doi:10.1016/j.it.2007.09.003)
63. Thornburg KL, O'Tierney P & Louey S 2010 The placenta is a programming agent in cardiovascular disease. Placenta 31 S54-S59. (doi:10.1016/j.placenta.2010.01.002)
64. Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB & Joyner-Grantham J 2009 Vasodilator factors in the systemic and local adaptations to pregnancy. Reproductive Biology and Endocrinology 7 79. (doi:10.1186/1477-7827-7-79)
65. Wang Q, Fujii H & Knipp GT 2002 Expression of PPAR and RXR isoforms in the developing rat and human term placentas. Placenta 23 661-671. (doi:10.1053/plac.2002.0855)
66. Webster RP, Roberts VH &Myatt L 2008 Protein nitration in placenta - functional significance. Placenta 29 985-994. (doi:10.1016/j.placenta. 2008.09.003)
67. Wieser F, Waite L, Depoix C & Taylor RN 2008 PPAR action in human placental development and pregnancy and its complications. PPAR Research 2008 527048. (doi:10.1155/2008/527048)
68. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, Kim JY, Park JJ, Kim JS, Bak YT et al. 2004 Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 19 799-804. (doi:10.1111/j.1440- 1746.2004.03349.x)
69. Yoon M 2009 The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacological Research 60 151-159. (doi:10.1016/j.phrs.2009.02.004)